Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium
AffiliationDepartment of Obstetrics and Gynecology, Henan Province People’s Hospital Zhengzhou, Henan, China
Department of Obstetrics and Gynecology, University of Arizona, Tucson, AZ, USA
Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, USA
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Shandong, China
Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
MetadataShow full item record
CitationWang et al. Journal of Hematology & Oncology 2013, 6:22 http://www.jhoonline.org/content/6/1/22
JournalJournal of Hematology & Oncology
Rights© 2013 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)
Collection InformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at firstname.lastname@example.org.
AbstractLynch syndrome (LS), an autosomal dominant inherited cancer susceptibility syndrome, also known as hereditary non-polyposis colon cancer (HNPCC), is caused by a germline mutation in one of several DNA mismatch repair (MMR) genes. LS is the most common presentation of hereditary colorectal cancer (CRC), accounting for about 2-5% of all CRC cases. More recently, it is found that a similar number of endometrial cancers is also due to one of the MMR gene mutations. There has been significant progress in LS-related CRC in terms of molecular pathogenesis, risks, genetic basis, and cancer prevention. In contrast, the advance about LS-related endometrial cancer (EC) is very much limited. In this commentary, we summarize the main clinicopathologic features of LS-related EC and propose universal screening for LS in individuals with endometrial cancer.
VersionFinal published version